Equaly
Private Company
Funding information not available
Overview
Equaly is an early-stage biotech leveraging a groundbreaking platform that targets antigen-specific innate immune cells to modulate immune responses. This approach has the potential to create novel vaccines, reduce immunogenicity of biological drugs, and develop curative therapies for autoimmune diseases. As a private, pre-revenue company likely in the pre-clinical stage, Equaly is positioned as a pioneer in a nascent field, seeking partnerships to advance its platform toward therapeutic applications.
Technology Platform
Platform modulating immune responses by targeting antigen-specific cells of the innate immune system to develop novel vaccines, de-immunize biologics, and create therapies for autoimmune conditions.
Opportunities
Risk Factors
Competitive Landscape
Equaly operates in the competitive immunotherapy space but claims a first-mover advantage in specifically targeting antigen-specific innate immune cells for therapy. It faces competition from companies developing adaptive immune therapies (e.g., CAR-T, bispecifics) and other innate immune modulators (e.g., TLR agonists, STING agonists), but its specific mechanism is distinct.